

## The terminator “Non-sense mediate mRNA decay”: Its role in the termination of intron containing a premature termination codon

Younis Skaik

doi: <http://dx.doi.org/10.12669/pjms.292.3429>

Human genes are composed of exons and interrupted by introns that must be removed by splicing to create a translatable mRNA. Alternative splicing is a vital pathway to regulate gene expression and increase the protein diversity.<sup>1,2</sup> In addition to skipping and inclusion of variable exons and usage of alternative splice sites,<sup>3</sup> intron retention is a third example of alternative splicing, whereby an intron sequence is retained or skipped in the mature mRNA transcript.<sup>4</sup> Notwithstanding intron retention potentially affects mRNA transport to the cytoplasm<sup>5</sup> and can insert a premature termination codon (PTC) and hence its degradation by the terminator (Non-sense mediate mRNA decay),<sup>6</sup> there is an evidence for mRNAs that containing intron and are encoding biologically active proteins.<sup>4</sup> The markedly increased alternative splicing of genes in human cancers<sup>7,8</sup> sheds the light on the possible pathways that might explain the exon containing PCT and whether they are sensitive or resistant to trigger the terminator.<sup>9</sup> However, to my knowledge, there are no studies that investigated the stealth pathway that the mRNAs transcripts intron-containing PTC<sup>10,11</sup> use to escape the radar (terminator). Hence, I would like to address the importance of such studies which will lead to therapeutic options which could suppress the production of the alternative spliced proteins through modulating and strengthen the terminator role.

---

Correspondence:

Younis Skaik,  
Department of Laboratory Medicine,  
Faculty of Applied Medical Sciences,  
AL-Azhar University-Gaza, Palestine.  
E-mail: [y\\_skaik@hotmail.com](mailto:y_skaik@hotmail.com)

\* Received for Publication: January 26, 2013

## REFERENCES

1. Black DL. Protein diversity from alternative splicing: a challenge for bioinformatics and post-genome biology. *Cell*. 2000;103(3):367-370.
2. Blencowe BJ. Alternative splicing: new insights from global analyses. *Cell*. 2006;126:37-47.
3. Stickeler E, Fraser SD, Honig A. The RNA binding protein YB-1 binds A/C-rich exon enhancers and stimulates splicing of the CD44 alternative exon v4. *EMBO J*. 2001;20(14):3821-3830.
4. Sakabe NJ, De Souza SJ. Sequence features responsible for intron retention in human. *BMC Genomics*. 2007;8:59.
5. Nott A, Meislin SH, Moore MJ. A quantitative analysis of intron effects on mammalian gene expression. *RNA*. 2003;9:607-617.
6. Lareau LF, Green RE, Bhatnagar RS. The evolving roles of alternative splicing. *Curr Opin Struct Biol*. 2004;14:273-282.
7. Pajares MJ, Ezponda T, Catena R. Alternative splicing: an emerging topic in molecular and clinical oncology. *Lancet Oncol*. 2007;8(4):349-357.
8. Skotheim RI, Nees M. Alternative splicing in cancer: noise, functional, or systematic? *Int J Biochem Cell Biol*. 2007;39:1432-1449.
9. Kalyna M, Simpson CG, Syed NH. Alternative splicing and nonsense-mediated decay modulate expression of important regulatory genes in Arabidopsis. *Nucleic Acids Res*. 2012;40:2454-2469.
10. Jin R, Trikha M, Cai Y. A naturally occurring truncated beta 3 integrin in tumor cells: native anti-integrin involved in tumor cell motility. *Cancer Biol Ther*. 2007;6:1559-1568.
11. Trikha M, Cai Y, Grignon D. Identification of a novel truncated alphaIIb integrin. *Cancer Res*. 1998;58(21):4771-4775.